Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Andreas Liebl"'
Publikováno v:
Frontiers in Built Environment, Vol 8 (2022)
High speech intelligibility in open-plan offices and thus a high changing-state character of the acoustic environment have been found to negatively influence cognitive performance. This is often attributed to the so-called irrelevant speech effect. O
Externí odkaz:
https://doaj.org/article/8e2bd1469a9c4c5bb8a4f76e57e9d9ed
Publikováno v:
Clinical Medicine Insights: Endocrinology and Diabetes, Vol 2015, Iss 8, Pp 13-19 (2015)
Externí odkaz:
https://doaj.org/article/90edb04634f649e0b639ae47ea5ae24c
Autor:
Mathias Basner, Mark Brink, Abigail Bristow, Yvonne de Kluizenaar, Lawrence Finegold, Jiyoung Hong, Sabine A Janssen, Ronny Klaeboe, Tony Leroux, Andreas Liebl, Toshihito Matsui, Dieter Schwela, Mariola Sliwinska-Kowalska, Patrik Sörqvist
Publikováno v:
Noise and Health, Vol 17, Iss 75, Pp 57-82 (2015)
The mandate of the International Commission on Biological Effects of Noise (ICBEN) is to promote a high level of scientific research concerning all aspects of noise-induced effects on human beings and animals. In this review, ICBEN team chairs and co
Externí odkaz:
https://doaj.org/article/7be7f4774fa048069b02860411dc1fd6
Publikováno v:
Noise and Health, Vol 17, Iss 76, Pp 148-157 (2015)
Little empirical evidence is available regarding the effects of road traffic noise on cognitive performance in adults, although traffic noise can be heard at many offices and home office workplaces. Our study tested the impact of road traffic noise a
Externí odkaz:
https://doaj.org/article/d34dcfd5bca144bd863edf00154e5d9d
Autor:
Andreas Liebl
Publikováno v:
BWK ENERGIE.. 75:22-24
Auf europäischer Ebene beschreibt der European Green Deal die Strategie der EU-Kommission, um in Europa bis zum Jahr 2050 Klimaneutralität zu erreichen. Künstliche Intelligenz kann dabei eine entscheidende Rolle spielen. Wie diese aussieht und wel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5e385bf29dabd94fa4cfed701e4ddc
https://doi.org/10.37544/1618-193x-2023-1-2-22
https://doi.org/10.37544/1618-193x-2023-1-2-22
Autor:
Athena Philis-Tsimikas, Vanita R. Aroda, Christophe De Block, Liana K. Billings, Andreas Liebl, Ramsathish Sivarathinasami, John M. D’Cruz, Ildiko Lingvay
Publikováno v:
Journal of Diabetes Science and Technology
Background: Derived time in range (dTIR), calculated from self-monitored blood glucose (SMBG-dTIR) profiles, has demonstrated correlation with risk of cardiovascular and microvascular complications. This post hoc analysis of the DUAL V and DUAL VIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b394e7f564caaf149b3cbc5a5ea611ac
https://hdl.handle.net/10067/1942690151162165141
https://hdl.handle.net/10067/1942690151162165141
Autor:
Andreas Liebl
Publikováno v:
Diabetes aktuell. 19:204-212
ZUSAMMENFASSUNGIn Deutschland sind eine Vielzahl basaler und prandialer Insuline auf dem Markt, die sich erheblich in ihrer Pharmakokinetik und in ihrem Einsatzbereich unterscheiden. Der Start einer Insulintherapie bei Typ-2-Diabetes erfolgt im Allge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88a3bbb0966f647f1ff7d43b35e96e1a
https://doi.org/10.1055/a-1576-9316
https://doi.org/10.1055/a-1576-9316
Publikováno v:
Mehta, R, Billings, L K, Liebl, A & Vilsbøll, T 2022, ' Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes ', Diabetic Medicine, vol. 39, no. 9, e14901 . https://doi.org/10.1111/dme.14901
Aims: Two fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) are available for once-daily use in adults with type 2 diabetes. We aimed to review the clinical evidence for the efficacy and safety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5a91db388b1ae055e0e23dd5e0b149e
https://curis.ku.dk/ws/files/321833797/Diabetic_Medicine_2022_Mehta_Transitioning_from_basal_bolus_or_premix_insulin_therapy_to_a_combination_of_basal.pdf
https://curis.ku.dk/ws/files/321833797/Diabetic_Medicine_2022_Mehta_Transitioning_from_basal_bolus_or_premix_insulin_therapy_to_a_combination_of_basal.pdf
Publikováno v:
Diabetes Therapy
Introduction Reducing dosing frequency may lower treatment burden and improve persistence and adherence. This retrospective, observational study assessed persistence and adherence in patients with type 2 diabetes (T2D) initiating once-weekly or daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2aacbec658ce99336ac406aad1462b
https://pubmed.ncbi.nlm.nih.gov/34918213
https://pubmed.ncbi.nlm.nih.gov/34918213
Publikováno v:
Diabetes. 70
Introduction: Reducing dosing frequency may reduce treatment burden and improve adherence and persistence. We assessed persistence and adherence in patients with T2D initiating once-weekly (OW) or once-daily (OD) injectable glucagon-like peptide-1 re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab5891aa8eaecb5474786d11fe2fdf9e
https://doi.org/10.2337/db21-83-lb
https://doi.org/10.2337/db21-83-lb